Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity

International Journal of Oncology

Volumn 38, Issue 6, 2011, Pages 1719-1729

  Fournier, Philippe ^a   Aigner, Maximilian ^a   Schirrmacher, Volker ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b IOZK   (Germany)

Author keywords

Antitumor vaccination; Bystander effect; Costimulation; Cytokines; Fusion protein; Granulocyte macrophage colony stimulating factor; Interleukin 2

Indexed keywords

CD14 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; INTERLEUKIN 2; RECOMBINANT ANTIBODY; RECOMBINANT PROTEIN; TUMOR VACCINE; VIRUS SIALIDASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; NEWCASTLE DISEASE PARAMYXOVIRUS; PRIORITY JOURNAL; PROTEIN STRUCTURE;

ANIMALS; BYSTANDER EFFECT; CANCER VACCINES; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; GENE ORDER; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; NEOPLASMS; NEWCASTLE DISEASE VIRUS; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS;

EID: 79955812364     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.976     Document Type: Article

References (52)

1. Liebrich W, Schlag P, Manasterski M, Lehner B, Stöhr M, Möller P and Schirrmacher V: In vitro and clinical characterisation of a Newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patients. Eur J Cancer 27: 703-710, 1991.
2. Schirrmacher V: Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunol Immunother 54: 587-598, 2005.
3. Ockert D, Schirrmacher V, Beck N, Stoelben E, Ahlert T, Flechtenmacher J, Hagmüller E, Buchcik R, Nagel M and Saeger HD: Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res 2: 21-28, 1996. (Pubitemid 26042174)
4. Schulze T, Kemmner W, Weitz J, Wernecke KD, Schirrmacher V and Schlag PM: Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol Immunother 58: 61-69, 2009.
5. Fournier P, Zeng J and Schirrmacher V: Two ways to induce innate immune responses in human PBMCs: paracrine stimulation of IFN-alpha responses by viral protein or dsRNA. Int J Oncol 23: 673-680, 2003.
6. Zeng J, Fournier P and Schirrmacher V: Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus. Virology 297: 19-30, 2002. (Pubitemid 34734906)
7. Ertel C, Millar NS, Emmerson PT, Schirrmacher V and von Hoegen P: Viral hemagglutinin augments peptide-specific cytotoxic T cell responses. Eur J Immunol 23: 2592-2596, 1993. (Pubitemid 23295144)
8. Termeer CC, Schirrmacher V, Brocker EB and Becker JC: Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells. Cancer Gene Ther 7: 316-323, 2000. (Pubitemid 30194568)
9. Fournier P, Aigner M and Schirrmacher V: Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine. Int Oncol 37: 1203-1217, 2010.
10. Fiola C, Peeters B, Fournier P, Arnold A, Bucur M and Schirrmacher V: Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int J Cancer 119: 328-338, 2006.
11. Sule NS, Nerurkar RP and Kamath S: Interleukin-2 as a therapeutic agent. J Assoc Physicians India 49: 897-900, 2001. (Pubitemid 33637315)
12. Arai KI, Lee F, Miyajima A, Miyatake S, Arai N and Yokota T: Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem 59: 783-836, 1990.
13. Rosenberg SA, Yang JC, White DE and Steinberg SM: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin2: identification of the antigens mediating response. Ann Surg 228: 307-319, 1998. (Pubitemid 30191694)
14. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX and Rosenberg SA: Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21: 3127-3132, 2003. (Pubitemid 46606294)
15. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT and Rosenberg SA: High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA 256: 3117-3124, 1986.
16. Bruton JK and Koeller JM: Recombinant interleukin-2. Pharmacotherapy 14: 635-656, 1994.
17. Xu X, Clarke P, Szalai G, Shively JE, Williams LE, Shyr Y, Shi E and Primus FJ: Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Cancer Res 60: 4475-4484, 2000. (Pubitemid 32103628)
18. Ruef C and Coleman DL: Granulocyte-macrophage colony-stimulating factor: pleiotropic cytokine with potential clinical usefulness. Rev Infect Dis 12: 41-62, 1990. (Pubitemid 20052765)
19. Pulendran B, Lingappa J, Kennedy MK, Smith J, Teepe M, Rudensky A, Maliszewski CR and Maraskovsky E: Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. J Immunol 159: 2222-2231, 1997. (Pubitemid 127681012)
20. Shen Z, Reznikoff G, Dranoff G and Rock KL: Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 158: 2723-2730, 1997. (Pubitemid 127470530)
21. Zou GM and Tam YK: Cytokines in the generation and maturation of dendritic cells: recent advances. Eur Cytokine Netw 13: 186-199, 2002. (Pubitemid 34747919)
22. Murtaza A, Kuchroo VK and Freeman GJ: Changes in the strength of co-stimulation through the B7/CD28 pathway alter functional T cell responses to altered peptide ligands. Int Immunol 11: 407-416, 1999. (Pubitemid 29121627)
23. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D and Mulligan RC: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539-3543, 1993. (Pubitemid 23111402)
24. Schirrmacher V, Haas C, Bonifer R, Ahlert T, Gerhards and Ertel C: Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther 6: 63-73, 1999. (Pubitemid 29043695)
25. Haas C, Lulei M, Fournier P, Arnold A and Schirrmacher V: T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine. Vaccine 23: 2439-2453, 2005.
26. Bian H, Fournier P, Moormann R, Peeters B and Schirrmacher V: Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus. Cancer Gene Ther 12: 295-303, 2005. (Pubitemid 40315189)
27. Haas C, Lulei M, Fournier P, Arnold A and Schirrmacher V: A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes. Int J Cancer 118: 658-667, 2006. (Pubitemid 43076015)
28. Diamantstein T and Osawa H: Studies on the interleukin-2 receptor, its generation and dynamics using monoclonal anti-interleukin-2 receptor antibodies. Mol Immunol 21: 1229-1236, 1984. (Pubitemid 15180844)
29. Heicappell R, Schirrmacher V, von Hoegen P, Ahlert T and Appelhans B: Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects. Int J Cancer 37: 569-577, 1986. (Pubitemid 16108598)
30. Lode HN, Xiang R, Becker JC, Gillies SD and Reisfeld RA: Immunocytokines: a promising approach to cancer immunotherapy. Pharmacol Ther 80: 277-292, 1998. (Pubitemid 28537824)
31. Becker JC, Pancook JD, Gillies SD, Mendelsohn J and Reisfeld RA: Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc Natl Acad Sci USA 93: 2702-2707, 1996. (Pubitemid 26114312)
32. Xiang R, Lode HN, Dolman CS, Dreier T, Varki NM, Qian X, Lo KM, Lan Y, Super M, Gillies SD and Reisfeld RA: Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res 57: 4948-4955, 1997. (Pubitemid 27469007)
33. Neal ZC, Yang JC, Rakhmilevich AL, Buhtoiarov IN, Lum HE, Imboden M, Hank JA, Lode HN, Reisfeld RA, Gillies SD and Sondel PM: Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clin Cancer Res 10: 4839-4847, 2004. (Pubitemid 38955538)
34. Kufer P, Mack M, Gruber R, Lutterbuse R, Zettl F and Riethmuller G: Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer. Cancer Immunol Immunother 45: 193-197, 1997. (Pubitemid 27521458)
35. Kufer P, Lutterbuse R and Baeuerle PA: A revival of bispecific antibodies. Trends Biotechnol 22: 238-244, 2004. (Pubitemid 38515741)
36. Hart DN: Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90: 3245-3287, 1997.
37. Wright-Browne V, McClain KL, Talpaz M, Ordonez N and Estrov Z: Physiology and pathophysiology of dendritic cells. Hum Pathol 28: 563-579, 1997. (Pubitemid 27213053)
38. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9: 271-296, 1991.
39. Guermonprez P, Valladeau J, Zitvogel L, Thery C and Amigorena S: Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20: 621-667, 2002. (Pubitemid 34293436)
40. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B and Palucka K: Immunobiology of dendritic cells. Annu Rev Immunol 18: 767811, 2000.
41. Dranoff G: GM-CSF-secreting melanoma vaccines. Oncogene 22: 3188-3192, 2003.
42. Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M and Dranoff G: Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res 60: 3239-3246, 2000. (Pubitemid 30407923)
43. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda Schmollinger JC, Hodi FS, Liebster L, Lam P, Mentzer S, Singer S, Tanabe KK, Cosimi AB, Duda R, Sober A, Bhan A, Daley J, Neuberg D, Parry G, Rokovich J, Richards L, Drayer J, Berns A, Clift S, Cohen LK, Mulligan RC and Dranoff G: Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 95: 13141-13146, 1998.
44. Yei S, Bartholomew RM, Pezzoli P, Gutierrez A, Gouveia E, Bassett D, Soo Hoo W and Carlo DJ: Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine. Gene Ther 9: 1302-1311, 2002.
45. Aigner M, Janke M, Lulei M, Beckhove P, Fournier P and Schirrmacher V: An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins. Int J Oncol 32: 777-789, 2008. (Pubitemid 351780588)
46. Schanzer JM, Baeuerle PA, Dreier T and Kufer P: A human cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM overexpressing tumor cells. Cancer Immun 6: 4, 2006.
47. Stagg, J, Wu JH, Bouganim and Galipeau J: Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy. Cancer Res 64: 8795-8799, 2004. (Pubitemid 39665478)
48. Schirrmacher V, Bai L, Umansky V, Yu L, Xing Y and Qian Z: Newcastle disease virus activates macrophages for anti-tumor activity. Int J Oncol 16: 363-373, 2000.
49. + memory T cells. Nature 441: 890-893, 2006.
50. Dumont FJ, Melino MR, Staruch MJ, Koprak SL, Fischer PA and Sigal NH: The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol 144: 1418-1424, 1990. (Pubitemid 20072915)
51. Schlom J, Sabzevari H, Grosenbach DW and Hodge JW: A triad of costimulatory molecules synergize to amplify T-cell activation in both vector-based and vector-infected dendritic cell vaccines. Artif Cells Blood Substit Immobil Biotechnol 31: 193-228, 2003. (Pubitemid 36560175)
52. Zhu M, Terasawa H, Gulley J, Panicali D, Arlen P, Schlom J and Tsang KY: Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res 61: 3725-3734, 2001. (Pubitemid 32694986)